Fig. 1

Patient disposition in the Rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and open-label extension (OLE). Percentages were calculated by dividing number of patients by total number of patients in each treatment arm (n = 127 for placebo, n = 492 for certolizumab pegol (CZP)). ^aTwo patients randomized in the placebo group received CZP 200 mg in the double-blind phase, and were analyzed as part of the safety population; ^bpatients who withdrew due to lack of efficacy at week 16 were eligible to enter the OLE; ^cat OLE entry all patients received 400 mg CZP + methotrexate every 2 weeks (Q2W), reduced to CZP 200 mg Q2W after ≥6 months; ^dpatients completed 232 weeks of CZP treatment from the first dose; ^enumber of withdrawers who entered the OLE differs from the number of week-16 withdrawers due to a windowing rule that resulted in a narrower group being defined for the week-16 withdrawers than actually were eligible for the OLE; week-16 withdrawers were defined as those who withdrew due to lack of efficacy at week 16, whereas withdrawers entering the RAPID 2 OLE included all withdrawers who entered the OLE, as recorded in the subject status evaluation. AE adverse event, ITT intention-to-treat, MTX methotrexate, RCT randomized controlled trial